GKOS
Glaukos CorpNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$6.68B
P/E Ratio
—
EPS
$-3.28
Beta
0.78
52W High
$130.23
52W Low
$73.16
50-Day MA
$111.93
200-Day MA
$100.01
Dividend Yield
—
Profit Margin
-37.00%
Forward P/E
2000.00
PEG Ratio
1.64
About Glaukos Corp
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Fundamentals
| Revenue (TTM) | $507.44M |
| Gross Profit (TTM) | $395.63M |
| EBITDA | $-48.64M |
| Operating Margin | -18.90% |
| Return on Equity | -26.40% |
| Return on Assets | -5.80% |
| Revenue/Share (TTM) | $8.87 |
| Book Value | $11.41 |
| Price-to-Book | 9.98 |
| Price-to-Sales (TTM) | 13.17 |
| EV/Revenue | 12.56 |
| EV/EBITDA | -57.89 |
| Quarterly Earnings Growth (YoY) | 1896.00% |
| Quarterly Revenue Growth (YoY) | 35.70% |
| Shares Outstanding | $58.08M |
| Float | $55.75M |
| % Insiders | 3.23% |
| % Institutions | 100.62% |
Analyst Ratings
Consensus ($138.75 target)
3
Strong Buy11
Buy1
SellData last updated: 4/8/2026